-
1 Comment
Shenzhen Salubris Pharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 11.4% below its 200 day moving average.
From a valuation standpoint, the stock is 43.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Shenzhen Salubris Pharmaceuticals Co., Ltd's total revenue sank by 33.3% to $604M since the same quarter in the previous year.
Its net income has dropped by 11759.5% to $-207M since the same quarter in the previous year.
Finally, its free cash flow fell by 78.4% to $22M since the same quarter in the previous year.
Based on the above factors, Shenzhen Salubris Pharmaceuticals Co., Ltd gets an overall score of 0/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100000FW8 |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | 43B |
|---|---|
| PE Ratio | 72.13 |
| Target Price | 44.135 |
| Dividend Yield | 1.3% |
| Beta | 0.71 |
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology, and cardiac rhythm management. In addition, the company develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in phase III clinical trial for treatment of hypertension; Enarodustat, a drug for renal anemia; SAL056, SAL001, SAL023 medicine used for treating osteoporosis; and Fotagliptin and SAL015 for diabetes which are under phase III clinical trial. Further, it develops Sacubitril Allisartan Calcium and SAL007 medicine for chronic heart failure; SAL003 to treat hypercholesterolemia; and SAL0114 for depressant indications that is in phase I clinical trial. Additionally, the company's preclinical products are SAL023 for osteoporosis; SAL0112 to treat diabetes; and SAL008 for the treatment of tumors. Furthermore, it develops medical devices, such as intracranial segment of vertebral artery stent, which is under clinical trials for Neurology intervention; SaExtenVena cava filter and Microneedle perfusion absolute ethanol delivery system used for Peripheral vascular intervention; and LAMax LAAC Left Atrial Appendage Occluder used for Structural heart disease. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002294.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
